Browse the evidence

Consuming ultra-processed milkshakes high in fat and sugar does not produce a statistically significant average increase in postingestive striatal dopamine release in healthy adults, refuting the hypothesis that such foods elicit drug-like dopamine responses.

The idea that ultra-processed foods trigger a massive, drug-like dopamine spike in your brain is not supported by this research. While individual responses vary, the average brain does not show a significant dopamine release after eating these foods. This suggests that overconsumption is likely driven more by behavioral factors, hunger, and hedonic preference (how much you like/want the food) rather than a fixed, overpowering biological addiction mechanism.

Adiposity (BMI, body fat percentage) is not significantly correlated with the magnitude of postingestive striatal dopamine response to ultra-processed foods, contradicting the hypothesis that obesity blunts this response.

Your body fat percentage does not determine how much your brain releases dopamine when you eat. This study found no link between being overweight and a 'blunted' dopamine response. This is encouraging: it means your brain's reward system is not permanently damaged by your weight, and you can influence your food preferences and intake through behavioral strategies.

Higher baseline BMI (30–40 kg/m²) correlates with lower health-related quality of life (utility indices), but the effect size is small (up to 0.005 per unit BMI) and often not statistically significant, suggesting BMI alone does not explain HRQoL differences.

While higher BMI is associated with slightly lower health utility scores, the impact is small and often not statistically significant. Do not assume your quality of life is defined by your BMI alone. Focus on managing specific comorbidities, age-related changes, and mental health, as these appear to be stronger drivers of your daily well-being than BMI itself.

Existing patient-reported outcome (PRO) measures for obesity fail to capture key appetite and eating behavior concepts (e.g., duration of fullness, satisfaction after eating, eating between meals) that are relevant to individuals with obesity and likely to change with treatment.

If you are managing obesity, standard questionnaires might miss how you actually feel after eating (satisfaction, fullness duration). This gap means your provider might not fully understand your specific challenges with cravings or portion control. A comprehensive assessment tool (like the EBAQ) can better capture these nuances to tailor your treatment plan.

Primary care physicians systematically overestimate the mortality risk associated with being overweight (BMI 25–29.9), perceiving a significantly higher risk increase than what current meta-analytic evidence supports.

Physicians should be aware that their perception of mortality risk for overweight patients (BMI 25-29.9) is likely inflated compared to actual population data. This overestimation may lead to unnecessary alarm or aggressive interventions for patients who are not obese. Counseling should focus on overall health metrics rather than BMI categories alone, recognizing that the mortality risk for 'overweight' is modest and inconsistent across studies.

DPP-4 inhibitors (Sitagliptin, Saxagliptin, Alogliptin, Linagliptin) are generally neutral for cardiovascular outcomes, with specific agents (Saxagliptin, Alogliptin) associated with an increased risk of heart failure hospitalization.

If you have Type 2 Diabetes and Heart Failure, avoid Saxagliptin and Alogliptin. DPP-4 inhibitors are generally neutral for heart health; prefer SGLT2 inhibitors or GLP-1 agonists which offer proven cardiovascular benefits.

In Japanese subjects, obesity (higher BMI) reduces the numerical incretin effect more significantly than glucose intolerance (T2D or IGT status).

If you have Type 2 Diabetes or pre-diabetes, focus on weight management to improve your body's natural hormonal response to food. In Japanese populations, losing weight improves the 'incretin effect' (how your gut signals your pancreas to make insulin) more effectively than just managing blood sugar numbers alone.

Gastrointestinally-mediated glucose disposal (GIGD), a measure of integrated glucose handling including glucagon suppression, is significantly reduced in Type 2 Diabetes and correlates with obesity.

Managing Type 2 Diabetes involves more than just stimulating insulin; it requires suppressing glucagon. Weight loss helps restore this balance, improving how your body disposes of glucose after a meal.

Leucine-rich high protein supplementation (50.6 g protein and 6 g leucine daily) does not significantly improve body composition or muscle function in older adults with sarcopenia over a 12-week period, despite upregulating specific gene expression related to ATP production and DNA repair.

For older adults with sarcopenia, taking leucine-rich protein supplements alone for 12 weeks will not significantly increase muscle mass or improve physical function. While it may positively influence gene expression related to energy production, it is not a standalone solution for reversing sarcopenia. To see functional benefits, supplementation should likely be combined with resistance exercise.

In elderly patients with type 2 diabetes, maintaining the Triglyceride-Glucose index combined with a Body Shape Index (TyG-ABSI) within an optimal range (specifically avoiding both extremely low and extremely high values) is associated with the lowest all-cause mortality risk.

If you have Type 2 Diabetes, standard weight metrics like BMI might not fully capture your mortality risk. Research suggests that a combination of insulin resistance markers (Triglyceride-Glucose index) and body shape (ABSI) provides a more accurate prediction of health outcomes. Crucially, this risk follows a 'U-shape': both extremely high and extremely low values of this combined index are associated with higher mortality. Therefore, the goal is not simply to minimize these numbers, but to maintain them within an optimal, balanced range, while closely monitoring kidney function (eGFR) as it mediates this risk.

Hypothalamic gliosis, measured via MRI T2 signal ratios, is positively associated with higher BMI, hypertension, metabolic syndrome, and lower HDL-C, independent of adiposity.

This research suggests that brain inflammation (gliosis) is linked to heart disease risks like high blood pressure and bad cholesterol, even if you aren't overweight. While you can't easily see this on an MRI, it implies that managing metabolic health through diet and exercise might protect your brain's regulatory centers, potentially lowering your cardiovascular risk.

Approximately 11.5% of patients undergoing secondary metabolic bariatric surgery (MBS) transfer to a different hospital than their primary procedure, a rate that is underestimated in single-institution registries.

If you are considering secondary bariatric surgery, be aware that about 11% of patients switch hospitals for this procedure. This is often driven by dissatisfaction with weight regain or complications from the first surgery. You are not alone in seeking a second opinion or a different provider if you feel your current care is not meeting your expectations.

Higher neighborhood-level socioeconomic disadvantage is associated with weaker statistical interactions (correlations) among the stages of adiposity, dysglycemia, and hypertension, suggesting that in disadvantaged populations, these cardiometabolic drivers develop more independently of one another.

If you live in a high-disadvantage neighborhood, standard assumptions about how weight affects blood sugar and blood pressure may not apply to you. The link between carrying extra weight and developing high blood sugar or high blood pressure is weaker in these settings. This suggests that factors like chronic stress, limited access to healthy food, and environmental stressors play a larger, independent role in your cardiometabolic health. Screening and prevention strategies should account for these social determinants rather than focusing solely on weight management.

Elevated Remnant Cholesterol Inflammatory Index (RCII) is independently associated with a significantly higher risk of incident cardiovascular disease (CVD), including heart disease and stroke.

If you are over 45, ask your doctor about your Remnant Cholesterol Inflammatory Index (RCII). It combines your cholesterol levels with inflammation markers to better predict heart disease risk than weight or BMI alone. High RCII indicates a need for targeted lifestyle interventions focusing on both lipid management and inflammation reduction.

RCII partially mediates the association between ABSI and incident CVD, with the mediation proportion increasing across higher ABSI quartiles.

Understanding that inflammation and lipid metabolism (RCII) play a role in how abdominal fat (ABSI) affects heart health can guide more targeted treatments. For those with high ABSI, addressing inflammation may provide additional cardiovascular protection beyond just weight management.

Prolonged oral processing (chewing) increases in vitro protein and lipid digestion efficiency by mechanically breaking down the food matrix, but this does not necessarily translate to altered in vivo glycaemic responses in healthy individuals.

For healthy individuals, chewing your food more thoroughly will help your stomach enzymes break down proteins and fats more efficiently in the lab setting, but it won't significantly change your blood sugar levels or metabolic health. If you have pre-diabetes, thorough chewing may help regulate blood sugar, but for the general healthy population, the food's physical structure (e.g., whole nuts vs. ground) matters more for nutrient absorption than chewing time alone.

The physical structure of plant-based foods (food matrix) acts as a barrier to nutrient digestion, meaning intact cell walls in nuts and grains reduce lipid and starch bioaccessibility compared to disintegrated foods.

When eating whole nuts or grains, your body may not absorb all the calories listed on the package because the tough cell walls protect some of the fats and starches from digestion. This means whole plant foods might be less calorie-dense than their labels suggest, but you should not rely on this to overconsume them.

High LDL-C and low HDL-C are more prevalent in women, while hypertriglyceridemia is more prevalent in men in the Iranian adult population.

Lipid profiles differ by gender. Women in this population showed higher rates of low HDL and high cholesterol, while men showed higher rates of high triglycerides. Regular lipid screening is important for both genders, with attention to these specific patterns.

Substituting plant-based meats for animal meats for 8 weeks does not significantly improve biomarkers of inflammation in generally healthy adults.

Swapping animal meat for plant-based meat alternatives for 8 weeks is unlikely to reduce your inflammation markers if your overall diet remains unchanged. These products are often ultra-processed, which may negate potential benefits. Focus on whole, unprocessed plant foods rather than just substituting meat analogues.

Kinovea video analysis software does not provide interchangeable or accurate measurements of barbell velocity, duration, or range of motion compared to the validated Open Barbell System (OBS) for free-weight resistance training exercises.

Do not use Kinovea to prescribe weights or determine when to stop a set based on velocity. It systematically overestimates speed and range of motion in free-weight lifts because it tracks the total path of the bar (including horizontal movement) rather than just vertical displacement. Use a validated linear position transducer (like the Open Barbell System) or percentage-based training if you cannot afford velocity equipment.

Intensive lifestyle intervention (ILI) targeting weight loss in adults with type 2 diabetes does not improve cognitive function and may leave a legacy of relative cognitive deficits in subgroups with baseline obesity or cardiovascular disease history, an effect not mediated by changes in leptin or VEGF levels.

For individuals with Type 2 Diabetes, especially those with obesity or heart disease history, intensive lifestyle interventions aimed at significant weight loss may not improve cognitive function and might be associated with relative cognitive declines compared to less intensive support. This decline was not explained by changes in leptin or VEGF. Patients should focus on overall metabolic health and cardiovascular risk reduction, but should not expect cognitive enhancement from weight loss alone, and should monitor for any subjective cognitive changes.

Moderate to severe weight change (loss or gain) of ≥5% within a 2-year interval is associated with a significantly increased risk of suicide mortality, exhibiting a reverse J-shaped curve.

If you experience rapid, unintentional weight loss or gain (≥5% in 2 years), it is a significant physiological stress signal. While weight loss is often pursued for health, rapid changes—especially if unexplained by diet/exercise—warrant medical and psychological evaluation to rule out underlying conditions or mental health risks, rather than simply viewing the change as a success or failure.

The Obesity Lifecycle Model demonstrates favorable concordance with observed clinical and quality-of-life outcomes, validating its use for evaluating obesity-related complications and informing healthcare decision making.

Healthcare decision-makers can use the Obesity Lifecycle Model to assess the cost-effectiveness of obesity therapies with confidence, as it has been validated to accurately predict clinical complications and quality-of-life impacts.

Both bariatric surgery (RYGB/SG) and structured medical treatment (VLED) result in similar safety profiles regarding hospitalization, need for further surgery, and mortality at 2-year follow-up, despite differences in weight loss magnitude.

Safety outcomes, including hospitalization and mortality, are comparable between bariatric surgery and structured medical treatment at 2 years. This suggests that for many patients, the higher efficacy of surgery does not come with a proportionally higher immediate safety risk compared to medical management.